INTERLEUKIN-18 GENE POLYMORPHISM AND SOME RISK FACTORS IN IRAQI PATIENTS WITH BREAST CANCER
DOI:
https://doi.org/10.22159/ajpcr.2017.v10i1.14487Abstract
Objective: Breast cancer is the most diagnosed cancer in women, which leads to death in a lot of women with breast cancer. The major risk factors associated with breast cancer risk related to family history, age, clinical history, lifestyle factors, long-period hormonal exposure, and single nucleotide polymorphisms in many genes showed possible links with breast cancer incidence risk in different people populations. Our study aimed to figure out the correlation between smoking, lodging and family history, and other factors with the risk of breast cancer.
Methods: Blood sample from female patients with breast cancer and healthy individuals were collected and subjected to tetra-amplification refractory mutation system–polymerase chain reaction (T-ARMS-PCR) technique for −607 C/A mutation of an interleukin (IL-18) gene and SPSS 18 software analyzed the results statically.
Results: Results showed no association between lodging and smoking with risk of breast cancer, (p>0.05), while the association between the risk and family history were obvious (p<0.05).
Conclusion: The results obtained by T-ARMS-PCR technique did not show the association between −607 C/An alternation of IL-18 gene and breast cancer (p>0.05) in the individuals examined in our study.
Keywords: Interleukin-18, Gene, Polymorphism, Tetra-amplification refractory mutation system–polymerase chain reaction, Mutations.
Downloads
References
Khuwaja GA, Abu-Rezq AN. Bimodal breast cancer classification system. Pattern Anal Appl 2004;7:235-42.
Al-Hashimi MM, Wang XJ. Breast cancer in Iraq, incidence trends from 2000-2009. Asian Pac J Cancer Prev 2014;15(1):281-6.
Garcia M, Jemal A, Ward EM. Global Cancer Facts & Figures. Atlanta, GA: American Cancer Society; 2007.
Mahdi KM, Nassiri MR, Nasiri K. Hereditary genes and SNPs associated with breast cancer. Asian Pac J Cancer Prev 2013;14(6):3403-9.
Cybulski C, Wokolorczyk D, Jakubowska A, Huzarski T, Byrski T, Gronwald J, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol 2011;29(28):3747-52.
Pooley KA, Healey CS, Smith PL, Pharoah PD, Thompson D, Tee L, et al. Association of the progesterone receptor gene with breast cancer risk: A single-nucleotide polymorphism tagging approach. Cancer Epidemiol Biomarkers Prev 2006;15(4):675-82.
Srivastava S, Salim N, Robertson MJ. Interleukin-18: Biology and role in the immunotherapy of cancer. Curr Med Chem 2010;17(29):3353-7.
Günel N, Coskun U, Sancak B, Günel U, Hasdemir O, Bozkurt S. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients. Cancer 2002;95(3):663-7.
Kruse S, Kuehr J, Moseler M, Kopp MV, Kurz T, Deichmann KA, et al. Polymorphisms in the IL 18 gene are associated with specific sensitization to common allergens and allergic rhinitis. J Allergy Clin Immunol 2003;111(1):117-22.
Tsai HT, Hsin CH, Hsieh YH, Tang CH, Yang SF, Lin CW, et al. Impact of interleukin-18 polymorphisms -607A/C and -137G/C on oral cancer occurrence and clinical progression. PLoS One 2013;8(12):e83572.
Nikiteas N, Yannopoulos A, Chatzitheofylaktou A, Tsigris C.
Heterozygosity for interleukin-18 -607 A/C polymorphism is associated with risk for colorectal cancer. Anticancer Res 2007;27(6B):3849-53.
Cunha LL, Tincani AJ, Assumpção LV, Soares FA, Vassallo J, Ward LS.
Interleukin-10 but not interleukin-18 may be associated with the immune response against well-differentiated thyroid cancer. Clinics (Sao Paulo) 2011;66(7):1203-8.
Jaiswal PK, Singh V, Srivastava P, Mittal RD. Association of IL-12, IL- 18 variants and serum IL-18 with bladder cancer susceptibility in North Indian population. Gene 2013;519(1):128-34.
Farjadfar A, Mojtahedi Z, Ghayumi MA, Erfani N, Haghshenas MR, Ghaderi A. Interleukin-18 promoter polymorphism is associated with lung cancer: A case-control study. Acta Oncol 2009;48(7):971-6.
Pratesi C, Bortolin MT, Bidoli E, Tedeschi R, Vaccher E, Dolcetti R, et al. Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother 2006;55(1):23-30.
Asefi V, Mojtahedi Z, Khademi B, Naeimi S, Ghaderi A. Head and neck squamous cell carcinoma is not associated with interleukin-18 promoter gene polymorphisms: A case-control study. J Laryngol Otol 2009;123(4):444-8.
Taheri M, Hashemi M, Eskandari-Nasab E, Fazaeli A, Arababi F, Bahrani-Zeidabadi M, et al. Association of -607 C/A polymorphism of IL-18 gene (rs1946518) with breast cancer risk in Zahedan, Southeast Iran. Prague Med Rep 2012;113(3):217-22.
Walker MJ. Breast Cancer Screening Behaviors and Outcomes in Women with a Family History of Breast and/or Ovarian Cancer in Ontario. Toronto, ON: Dalla Lana School of Public Health, University of Toronto; 2014.
Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: A systematic review and meta-analysis. Int J Cancer 1997;71(5):800-9.
Bevier M, Sundquist K, Hemminki K. Risk of breast cancer in families of multiple affected women and men. Breast Cancer Res Treat 2012;132(2):723-8.
Park S, Cheon S, Cho D. The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol 2007;4(5):329-35.
Yao L, Zhang Y, Chen K, Hu X, Xu LX. Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox. PLoS One 2011;6(9):e24684.
Giedraitis V, He B, Huang WX, Hillert J. Cloning and mutation analysis of the human IL-18 promoter: A possible role of polymorphisms in expression regulation. J Neuroimmunol 2001;112(1-2):146-52.
Arimitsu J, Hirano T, Higa S, Kawai M, Naka T, Ogata A, et al. IL-18 gene polymorphisms affect IL-18 production capability by monocytes. Biochem Biophys Res Commun 2006;342(4):1413-6.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
